NCT01042873

The Hemodynamic Response to Prolonged Dobutamine Infusion

• Status: Unknown
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 100 (estimated)
• Sponsor: Hadassah Medical Organization · Academic / Other
• Sex: All
• Age: 18 Years – 40 Years
• Healthy volunteers: Accepted

Summary

A decrease in the response of beta 1 adrenergic receptors to agonists (desensitization) is thought to play a major role in the pathogenesis of diseases such as congestive heart failure. However, currently, there is no in vivo model that will enable us to measure desensitization of the hemodynamic responses to beta 1 adrenergic receptors in vivo. Our hypothesis is that constant 3 hours intravenous infusion of the selective beta1 adrenergic receptor agonist dobutamine will result in gradual decline in hemodynamic responses to dobutamine over time.

Conditions

• Healthy
• Heart Failure

Interventions

Type	Name	Description
DRUG	3 hours intravenous dobutamine	Intravenous dobutamine will be infused during 3 hours. At the first and last 0.5 hors of infusion dose will be increased gradually, while in the middle 2 hours dose will remain constant.

Timeline

• Start date: 2010-01-01
• Primary completion: 2020-12-01
• Completion: 2021-12-01
• First posted: 2010-01-06
• Last updated: 2018-06-12

Locations

1 site across 1 country: Israel